Nanocurcumin formulation: a possible therapeutic agent for post COVID inflammatory syndrome.

Abstract

Over the last twenty months, the attention of the world has been focusing on managing the unprecedented and devastating wave of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV 2) and mitigating its impacts. Recent findings indicated that high levels of pro-inflammatory cytokines are leading cause of poor prognosis in severely ill COVID-19 patients. Presently, the multiple variants and highly contagious nature of virus makes challenge humongous. The shortage and vaccine hesitancy also prompted to develop antiviral therapeutic agents to manage this pandemic. Nanocurcumin has potential antiviral activities and also beneficial in post COVID inflammatory complications. We have developed nanocurcumin based formulation using pyrroloquinoline quinone (PQQ) which protects cardio-pulmonary function and mitochondrial homeostasis in hypobaric hypoxia induced right ventricular hypertrophy in animal model and human ventricular cardiomyocytes. Nanocurcumin based formulation (NCF) with improved bioavailability, has proven several holistic therapeutic effects including myocardial protection, and prevents edema formation, anti-inflammatory and antioxidant properties, maintaining metabolic and mitochondrial homeostasis under hypoxic condition. The post COVID-inflammatory syndrome also reported to cause impaired heart function, lung injuries and increased C-reactive protein level in severely ill patients. Thus, we speculate that NCF could be a new treatment option to manage post COVID-19 inflammatory syndrome.

• Authors: Asha D Kushwaha, K P Mishra, Mrinalini Singh, Lilly Ganju, Deepika Saraswat
• Journal: Immunopharmacology and immunotoxicology (Immunopharmacol Immunotoxicol) Vol. 44 Issue 2 Pg. 141-146 (Apr 2022) ISSN: 1532-2513 [Electronic] England
• PMID: 35130792 (Publication Type: Journal Article)

Chemical References

• Antioxidants

Topics

• Animals
• Antioxidants (pharmacology)
• Humans
• Hypoxia (drug therapy, metabolism)
• Mitochondria
• Pandemics
• COVID-19 Drug Treatment